Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Boryung Pharma Seeking MNCs To Sell Hypertension Product Abroad

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Boryung Pharma is seeking multinational partners to out-license its angiotensin receptor blocker Kanarb (fimasartan) in the U.S. and Europe

You may also be interested in...



After Mexican Marketing Deal, Korea's Boryung Ventures Into Central And South America

SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries

After Mexican Marketing Deal, Korea's Boryung Ventures Into Central And South America

SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries

Korea's Boryung Takes Hypertension Drug Kanarb Beyond Korea With Stendhal Deal

SEOUL - Boryung Pharma signed a licensing agreement with Stendhal International, a Mexico-based company, to supply the South Korean company's angiotensin receptor blocker Kanarb (fimasartan) for $22.6 million, marking the first time Kanarb will be sold outside of Korea

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel